AbbVie has completed its $10.9-billion acquisition of Apogee Therapeutics, a Waltham, Massachusetts-based clinical-stage bio/pharmaceutical company.  

Apogee’s lead assets are zumilokibart, a subcutaneous half-life extended monoclonal antibody for treating atopic dermatitis (eczema) in Phase II development, and APG273, a combination of zumilokibart and APG333, an antibody that blocks thymic stromal lymphopoietin, a signaling protein that acts as an early trigger of inflammation in the lungs. APG273 is in Phase I development for treating asthma. Zumilokibart targets IL-13, a critical cytokine in Type 2 inflammation in diseases such as atopic dermatitis and asthma. Beyond zumilokibart, Apogee has a broader pipeline of antibodies targeting multiple validated inflammatory pathways. 

AbbVie acquired all outstanding Apogee common stock for $135.11 per share in cash, for a total equity value of approximately $10.9 billion.  

Source: AbbVie